Published in Eur Heart J on November 16, 2011
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med (2013) 2.33
Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines. BMC Med (2013) 1.27
Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes (2014) 1.07
Management of carotid stenosis in women: consensus document. Neurology (2013) 0.81
A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs (2015) 0.78
Utility of different cardiovascular disease prediction models in rheumatoid arthritis. J Med Life (2015) 0.77
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making (2006) 11.83
Review: a gentle introduction to imputation of missing values. J Clin Epidemiol (2006) 8.87
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 7.34
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95
Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med (2000) 4.84
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Aspirin: a historical and contemporary therapeutic overview. Circulation (2011) 1.74
Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials (2007) 1.58
Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ (2011) 1.32
Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence? Future Cardiol (2010) 0.81
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Inflammation and atherosclerosis. Circulation (2002) 20.77
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Statins: new American guidelines for prevention of cardiovascular disease. Lancet (2013) 9.56
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet (2010) 6.94
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Physical activity and weight gain prevention. JAMA (2010) 5.27
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ (2009) 4.98
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J (2008) 4.74
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Prevalence of dry eye syndrome among US women. Am J Ophthalmol (2003) 4.46
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem (2007) 4.45
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Inflammation as a cardiovascular risk factor. Circulation (2004) 4.26
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 3.92
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension (2013) 3.81
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81